Skip to main content

Table 1 Baseline characteristics of patients with critical COVID-19 admitted from March 2020 to May 2021 to ICUs at the participating hospitals with no diagnosis of TE or major bleeding at admission

From: A retrospective multicenter cohort study of the association between anti-Factor Xa values and death, thromboembolism, and bleeding in patients with critical COVID-19

Characteristic

All patients (n = 1140)

Patients with peak values (n = 153)

Patients with trough value (n = 300)

Hospital

 Södersjukhuset

625 (54.8)

57 (37.3)

88 (29.3)

 Karolinska University Hospital

426 (37.3)

47 (30.7)

209 (69.7)

 Skåne University Hospital

89 (7.8)

49 (32.0)

3 (1.0)

Age, median (IQR), years

63 (54 to 71)

64 (55 to 70)

63 (54 to 69)

Sex

 Male

840 (73.7)

128 (83.7)

225 (75.0)

 Female

300 (26.3)

25 (16.3)

75 (25.0)

 BMI, median (IQR), kg/m2

(n = 1109)

29 (26 to 33)

(n = 144)

29 (26 to 34)

(n = 296)

29 (26 to 35)

Coexisting conditions

 Hypertension

576 (50.5)

77 (50.3)

159 (53.0)

 Diabetes mellitus

285 (25.0)

42 (27.4)

74 (24.7)

 Heart disease (IHD, Heart failure, Atrial fibrillation/flutter)

194 (17.0)

22 (14.4)

49 (16.3)

 Chronic pulmonary disease

266 (23.3)

29 (19.0)

73 (24.3)

 Immunosuppressive

77 (6.8)

10 (6.5)

30 (10.0)

 Prior venous thromboembolic disease (no longer treated)

51 (4.5)

2 (1.3)

14 (4.7)

 Prior cerebrovascular disease

82 (7.2)

8 (5.2)

22 (7.3)

 Renal disease

95 (8.3)

11 (7.2)

28 (9.3)

 Liver disease

38 (3.3)

5 (3.3)

13 (4.3)

 Malignancy

113 (9.9)

9 (5.9)

35 (11.7)

Chronic use of medication

 Systemic glucocorticoids

84 (7.4)

13 (8.5)

24 (8.0)

 Direct oral anticoagulants

78 (6.8)

5 (3.3)

19 (6.3)

 Vitamin K antagonists

13 (1.1)

0 (0)

3 (1.0)

 Platelet inhibitors

153 (13.4)

24 (15.7)

35 (11.7)

 SAPS III- score, median (IQR)

(n = 1086)

56 (51 to 63)

(n = 142)

58 (53 to 64)

(n = 280)

57 (50 to 62)

 PaO2/FiO2 at admission, median (IQR)

(n = 966)

11 (9.0 to 14)

(n = 97)

11 (8.9 to 14)

(n = 273)

11 (8.6 to 13)

 Limitations of care (life support or CPR)

83 (7.3)

4 (2.6)

15 (5.0)

 Time from onset of symptoms to ICU admission, median (IQR), days

(n = 1139)

10 (7 to 13)

9 (7 to 12)

10 (7 to 12)

Respiratory support during current admission

 High flow nasal cannula

(n = 1051)

572 (54.4)

(n = 104)

48 (46)

(n = 297)

124 (41.8)

 Noninvasive ventilation

(n = 1051)

426 (40.5)

(n = 104)

27 (26)

(n = 297)

161 (54.2)

 Invasive ventilation

735 (64.5)

145 (95)

227 (75.7)

Therapy during current admission

 Glucocorticoids

942 (82.6)

126 (82.4)

293 (97.7)

 IL-6 inhibitor

158 (13.9)

11 (7.2)

69 (23.0)

 Remdesivir

137 (12.0)

13 (8.5)

55 (18.3)

 Platelet inhibitors

(n = 815)

153 (18.8)

(n = 63)

24 (38.1)

(n = 265)

67 (25.3)

Initial dose of LMWHa

 High LMWH doseb

(n = 1100)

299 (27.2)

(n = 147)

22 (15.0)

(n = 288)

71 (24.7)

 Intermediate LMWH dosec

(n = 1100)

636 (57.8)

(n = 147)

95 (64.6)

(n = 288)

194 (67.4)

 Low LMWH dosed

(n = 1100)

142 (12.9)

(n = 147)

30 (19.6)

(n = 288)

22 (7.6)

 No prophylaxis

(n = 1100)

18 (1.6)

(n = 147)

0 (0)

(n = 288)

1 (0.3)

 Other drug than LMWH

(n = 1100)

5 (0.5)

(n = 147)

0

(n = 147)

0

Type of LMWH

 Tinzaparin

(n = 1010)

558 (55.2)

56 (36.6)

81 (27.0)

 Dalteparin

(n = 1010)

367 (36.3)

48 (31.4)

216 (72.0)

 Enoxaparin

(n = 1010)

85 (8.4)

49 (32.0)

3 (1.0)

Laboratory markerse

 Hemoglobin, median (IQR), g/L

(n = 1033)

131 (119 to 141)

(n = 140)

133 (121 to 147)

(n = 281)

132 (119 to 141)

 Leucocyte count, median (IQR), 10^9/L

(n = 995)

8.8 (6.5 to 11.8)

(n = 136)

8.8 (6.0 to 12)

(n = 272)

8.5 (6.3 to 11)

 Platelet count, median (IQR), 10^9/L

(n = 994)

238 (182 to 307)

(n = 136)

235 (178 to 311)

(n = 271)

225 (178 to 283)

 Activated partial thrombin time, median (IQR), seconds

(n = 720)

27 (24 to 30)

(n = 99)

28 (25 to 31)

(n = 251)

26 (24 to 30)

 Prothrombin time, median (IQR), INR

(n = 959)

1.1 (1 to 1.2)

(n = 133)

1.1 (1 to 1.2)

(n = 267)

1.1 (1 to 1.2)

 Fibrin-D-dimer, median (IQR), mg/L FEU

(n = 906)

1.2 (0.8 to 2.4)

(n = 126)

1.5 (0.8 to 2.8)

(n = 264)

1.2 (0.7 to 2.3)

 CRP, median (IQR), mg/L

(n = 994)

148 (92 to 224)

(n = 153)

154 (100 to 236)

(n = 272)

145 (87 to 217)

 Procalcitonin, median (IQR), µg/L

(n = 904)

0.36 (0.18 to 0.97)

(n = 93)

0.46 (0.23 to 1.2)

(n = 263)

0.38 (0.17 to 1.2)

 Bilirubin, median (IQR), µmol/L

(n = 976)

8 (5 to 11)

(n = 133)

8 (6 to 11)

(n = 269)

7 (5 to 11)

 Fibrinogen, median (IQR), g/L

(n = 706)

6.3 (5.1 to 7.4)

(n = 92)

6.5 (5.3 to 7.7)

(n = 250)

6.0 (4.9 to 7.2)

 Creatinine, median (IQR), µmol/L

(n = 1032)

70 (57 to 92)

(n = 152)

75 (60 to 100)

(n = 299)

71 (58 to 93)

 eGFR by CKDEpi, median (IQR), ml/min/1.73 m2

(n = 1032)

97 (76 to 107)

(n = 152)

95 (70 to 106)

(n = 299)

96 (73 to 107)

 Patients with eGFR below 30 by CKDEpi, ml/min/1.73 m2

(n = 1032)

58 (5.6)

(n = 152)

12 (7.9)

(n = 299)

20 (6.7)

 Patients with eGFR below 60 by CKDEpi, ml/min/1.73 m2

(n = 1032)

172 (16.7)

(n = 152)

28 (18.4)

(n = 299)

50 (16.7)

 Patients with eGFR below 90 by CKDEpi, ml/min/1.73 m2

(n = 1032)

393 (38.1)

(n = 152)

62 (40.5)

(n = 299)

116 (38.7)

  1. Baseline characteristics of 1,140 patients, admitted to the ICU from March 2020 to May 2021 due to critical COVID-19
  2. Values are expressed as no. (%) unless otherwise indicated. Data are complete for all included patients unless indicated by the number of patients
  3. Abbreviations: BMI body mass index, IHD ischemic heart disease, SAPS III Simplified Acute Physiology Score III, PaO2/FiO2 partial pressure of oxygen/fraction of inspired oxygen, IL-6 interleukin-6, LMWH low-molecular-weight heparin, INR international normalized ratio, FEU fibrinogen equivalent unit, CRP C-reactive protein, CPR cardiopulmonary resuscitation, eGFR estimated glomerular filtration rate, CKDEpi Chronic Kidney Disease Epidemiology Collaboration, ICU intensive care unit, aFXa anti-Factor Xa
  4. aAt ICU admission defined as the first date during the ICU stay
  5. bTinzaparin, ≥ 175 IU/kg of body weight per daily, dalteparin, ≥ 200 IU/kg of body weight daily, or enoxaparin, ≥ 2 mg/kg of body weight daily
  6. cTinzaparin, > 4500 IU daily to < 175 IU/kg of body weight daily, or dalteparin, > 5000 IU daily to < 200 IU/kg of body weight daily, or enoxaparin, > 40 mg but < 2 mg/kg of body weight daily
  7. dTinzaparin, 2500–4500 IU daily, dalteparin, 2500–5000 IU daily, or enoxaparin, ≤ 40 mg daily
  8. eBaseline laboratory values defined as those sampled within 48 h of ICU admission
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us